SVP of Clinical Operations Harry Alcorn resigns from DiaMedica; separation agreement includes salary continuation

DiaMedica Therapeutics Inc.

Harry Alcorn, Jr., Pharm.D., SVP of Clinical Operations, resigned effective May 23, 2022.
Separation agreement provides salary continuation for 9 months (up to 12 if unemployed), COBRA, pro-rata bonus, and option acceleration.
Entered consulting agreement at $200/hour; no fees while receiving salary continuation.
Alcorn must cooperate with transition, maintain confidentiality, and non-disparagement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Harry Alcorn, Jr.

Senior Vice President of Clinical Operations

DMAC · DiaMedica Therapeutics Inc.

Effective: 2022-05-23
Filed: May 25, 2022, 7:59 PM ET

On May 23, 2022, Harry Alcorn, Jr., Pharm.D., Senior Vice President of Clinical Operations of DiaMedica Therapeutics Inc. (the “Company”), resigned as an officer and employee of the Company and its subsidiaries, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Harry Alcorn, Jr. resigned as Senior Vice President of Clinical Operations at DiaMedica Therapeutics Inc..

Action: resigned
Role: Senior Vice President of Clinical Operations

Exact text from the filing

On May 23, 2022, Harry Alcorn, Jr., Pharm.D., Senior Vice President of Clinical Operations of DiaMedica Therapeutics Inc. (the “Company”), resigned as an officer and employee of the Company and its subsidiaries, effective immediately.

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-013555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.